Dyne Therapeutics, Inc. 8K

Dyne Therapeutics reported Q2 2026 results while announcing major clinical and regulatory milestones for its neuromuscular pipeline, substantial debt and equity financings, and an extended cash runway into Q2 2028 as it advances toward potential commercialization of z-rostudirsen and z-basivarsen.

On July 29, 2026, Dyne Therapeutics, Inc. reported its second quarter 2026 financial results and provided significant clinical, regulatory and financing updates, including FDA acceptance with Priority Review of its Biologics License Application for z-rostudirsen (DYNE-251) for exon 51 Duchenne muscular dystrophy with a PDUFA target date of January 21, 2027, completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial and initiation of the Phase 3 HARMONIA trial for z-basivarsen (DYNE-101) in DM1 with topline data expected in Q1 2027 and a potential BLA in Q3 2027, FDA clearance of an IND for DYNE-302 in FSHD enabling a Phase 1 trial, expansion of its Hercules Capital senior secured term loan facility to up to $400 million, completion of an underwritten public equity offering raising approximately $431 million gross (about $405 million net), and an updated cash runway projection into the second quarter of 2028 alongside reporting a quarterly net loss of $178.6 million driven by increased R&D and G&A expenses as the company prepares for potential commercialization.

Filing Facts

CIK

1818794

Ticker

DYN

Form

8K

Source Type

fda

Accession

0001193125-26-323940

Alert Tier

7